202 related articles for article (PubMed ID: 35905928)
1. Inhibition of PLK2 activity affects APP and tau pathology and improves synaptic content in a sex-dependent manner in a 3xTg mouse model of Alzheimer's disease.
Martínez-Drudis L; Sheta R; Pellegrinato R; Loukili S; Tremblay C; Calon F; Rivest S; Oueslati A
Neurobiol Dis; 2022 Oct; 172():105833. PubMed ID: 35905928
[TBL] [Abstract][Full Text] [Related]
2. Sex Differences in Neuropathology and Cognitive Behavior in APP/PS1/tau Triple-Transgenic Mouse Model of Alzheimer's Disease.
Yang JT; Wang ZJ; Cai HY; Yuan L; Hu MM; Wu MN; Qi JS
Neurosci Bull; 2018 Oct; 34(5):736-746. PubMed ID: 30099679
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Polo-like kinase 2 ameliorates pathogenesis in Alzheimer's disease model mice.
Lee JS; Lee Y; André EA; Lee KJ; Nguyen T; Feng Y; Jia N; Harris BT; Burns MP; Pak DTS
PLoS One; 2019; 14(7):e0219691. PubMed ID: 31306446
[TBL] [Abstract][Full Text] [Related]
4. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective Effect of SLM, a Novel Carbazole-Based Fluorophore, on SH-SY5Y Cell Model and 3xTg-AD Mouse Model of Alzheimer's Disease.
Wu X; Kosaraju J; Zhou W; Tam KY
ACS Chem Neurosci; 2017 Mar; 8(3):676-685. PubMed ID: 28032988
[TBL] [Abstract][Full Text] [Related]
6. 3×Tg-AD Mice Overexpressing Phospholipid Transfer Protein Improves Cognition Through Decreasing Amyloid-β Production and Tau Hyperphosphorylation.
Wang WZ; Li MW; Chen Y; Liu LY; Xu Y; Xia ZH; Yu Y; Wang XD; Chen W; Zhang F; Xu XY; Gao YF; Zhang JG; Qin SC; Wang H
J Alzheimers Dis; 2021; 82(4):1635-1649. PubMed ID: 34219730
[TBL] [Abstract][Full Text] [Related]
7. FAK-Mediated Signaling Controls Amyloid Beta Overload, Learning and Memory Deficits in a Mouse Model of Alzheimer's Disease.
Saleh B; Srikanth KD; Sneh T; Yue L; Pelech S; Elliott E; Gil-Henn H
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012331
[TBL] [Abstract][Full Text] [Related]
8. Tau passive immunization inhibits not only tau but also Aβ pathology.
Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
[TBL] [Abstract][Full Text] [Related]
9. Theranostic F-SLOH mitigates Alzheimer's disease pathology involving TFEB and ameliorates cognitive functions in Alzheimer's disease models.
Iyaswamy A; Wang X; Krishnamoorthi S; Kaliamoorthy V; Sreenivasmurthy SG; Kumar Durairajan SS; Song JX; Tong BC; Zhu Z; Su CF; Liu J; Cheung KH; Lu JH; Tan JQ; Li HW; Wong MS; Li M
Redox Biol; 2022 May; 51():102280. PubMed ID: 35286997
[TBL] [Abstract][Full Text] [Related]
10. Ca2+-permeable TRPV1 pain receptor knockout rescues memory deficits and reduces amyloid-β and tau in a mouse model of Alzheimer's disease.
Kim J; Lee S; Kim J; Ham S; Park JHY; Han S; Jung YK; Shim I; Han JS; Lee KW; Kim J
Hum Mol Genet; 2020 Jan; 29(2):228-237. PubMed ID: 31814000
[TBL] [Abstract][Full Text] [Related]
11. Fyn knock-down increases Aβ, decreases phospho-tau, and worsens spatial learning in 3×Tg-AD mice.
Minami SS; Clifford TG; Hoe HS; Matsuoka Y; Rebeck GW
Neurobiol Aging; 2012 Apr; 33(4):825.e15-24. PubMed ID: 21741124
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of chronic immunosuppression on behavioral, epigenetic, and Alzheimer's disease-associated markers in 3xTg-AD mice.
Kapadia M; Mian MF; Ma D; Hutton CP; Azam A; Narkaj K; Cao C; Brown B; Michalski B; Morgan D; Forsythe P; Zovkic IB; Fahnestock M; Sakic B
Alzheimers Res Ther; 2021 Jan; 13(1):30. PubMed ID: 33472690
[TBL] [Abstract][Full Text] [Related]
13. Dyrk1 inhibition improves Alzheimer's disease-like pathology.
Branca C; Shaw DM; Belfiore R; Gokhale V; Shaw AY; Foley C; Smith B; Hulme C; Dunckley T; Meechoovet B; Caccamo A; Oddo S
Aging Cell; 2017 Oct; 16(5):1146-1154. PubMed ID: 28779511
[TBL] [Abstract][Full Text] [Related]
14. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease.
Manczak M; Reddy PH
Hum Mol Genet; 2012 Dec; 21(23):5131-46. PubMed ID: 22926141
[TBL] [Abstract][Full Text] [Related]
15. Reducing Ribosomal Protein S6 Kinase 1 Expression Improves Spatial Memory and Synaptic Plasticity in a Mouse Model of Alzheimer's Disease.
Caccamo A; Branca C; Talboom JS; Shaw DM; Turner D; Ma L; Messina A; Huang Z; Wu J; Oddo S
J Neurosci; 2015 Oct; 35(41):14042-56. PubMed ID: 26468204
[TBL] [Abstract][Full Text] [Related]
16. Reversal of memory and neuropsychiatric symptoms and reduced tau pathology by selenium in 3xTg-AD mice.
Van der Jeugd A; Parra-Damas A; Baeta-Corral R; Soto-Faguás CM; Ahmed T; LaFerla FM; Giménez-Llort L; D'Hooge R; Saura CA
Sci Rep; 2018 Apr; 8(1):6431. PubMed ID: 29691439
[TBL] [Abstract][Full Text] [Related]
17. Sex-Dependent Differences in Spontaneous Autoimmunity in Adult 3xTg-AD Mice.
Kapadia M; Mian MF; Michalski B; Azam AB; Ma D; Salwierz P; Christopher A; Rosa E; Zovkic IB; Forsythe P; Fahnestock M; Sakic B
J Alzheimers Dis; 2018; 63(3):1191-1205. PubMed ID: 29710702
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a 3xTg-AD mouse model of Alzheimer's disease with the senescence accelerated mouse prone 8 (SAMP8) background.
Virgili J; Lebbadi M; Tremblay C; St-Amour I; Pierrisnard C; Faucher-Genest A; Emond V; Julien C; Calon F
Synapse; 2018 Apr; 72(4):. PubMed ID: 29341269
[TBL] [Abstract][Full Text] [Related]
19. Reduced Reelin expression accelerates amyloid-beta plaque formation and tau pathology in transgenic Alzheimer's disease mice.
Kocherhans S; Madhusudan A; Doehner J; Breu KS; Nitsch RM; Fritschy JM; Knuesel I
J Neurosci; 2010 Jul; 30(27):9228-40. PubMed ID: 20610758
[TBL] [Abstract][Full Text] [Related]
20. L-3-n-butylphthalide improves cognitive impairment and reduces amyloid-beta in a transgenic model of Alzheimer's disease.
Peng Y; Sun J; Hon S; Nylander AN; Xia W; Feng Y; Wang X; Lemere CA
J Neurosci; 2010 Jun; 30(24):8180-9. PubMed ID: 20554868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
